Wells Fargo analyst Yanan Zhu has maintained their neutral stance on EDIT stock, giving a Hold rating today.
Yanan Zhu has given his Hold rating due to a combination of factors related to Editas Medicine’s current financial and strategic position. The company reported a net loss per share that was greater than consensus expectations, highlighting ongoing financial challenges. Despite this, Editas maintains a solid cash position, which is expected to support operations into the second quarter of 2027, providing some financial stability.
Additionally, Editas is making progress in its in vivo programs, with significant milestones anticipated in mid-2025. The company is on track to declare development candidates for both hematopoietic stem cell and liver editing programs, with promising preclinical data already reported. However, the recent headcount reduction and discontinuation of certain programs indicate restructuring efforts that may pose risks. These mixed signals contribute to the Hold rating, as the potential for future growth is balanced by current uncertainties.
In another report released today, Barclays also maintained a Hold rating on the stock with a $3.00 price target.